2150. In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021

BACKGROUND: Taniborbactam, a cyclic boronate-based β-lactamase inhibitor with activity against serine-, and NDM & VIM metallo-β-lactamases (MBLs), in combination with the fourth-generation cephalosporin, cefepime, is in development for treatment of complicated urinary tract infections. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Wise, Mark G, Hackel, Meredith, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677560/
http://dx.doi.org/10.1093/ofid/ofad500.1773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677560/
http://dx.doi.org/10.1093/ofid/ofad500.1773

Ejemplares similares